Daniel Spratt

65PUBLICATIONS
343CO-AUTHORS
Decision makingPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Oct 08, 2026
Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.

|Sep 26, 2026
External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

|Apr 30, 2026
Trends in Long-Term Survival Among Patients With De Novo Metastatic Cancer.

|Apr 29, 2026
Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy.

|Feb 19, 2026
Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study.

Sean M McBride, Daniel E Spratt, Marisa Kollmeier

Pageof 11

Frequent Collaborators

10 joint publications

Robert T Dess

10 joint publications

Mary Feng

10 joint publications

Soumyajit Roy

9 joint publications

Amar U Kishan